Complaint “to recover significant investment losses suffered as a result of a massive fraud that led investors to believe that Teva – the world’s largest generic drug manufacturer – was experiencing strong financial growth over a number of years based on fundamentally sound business practices when, in fact, Teva’s performance was being driven by an illegal practice of colluding with other drug manufacturers to systematically increase the price of scores of generic drugs” in BH Investments Funds LLC, Brahman Partners III LP, Brahman Partners II LP, Brahman Partners IV LP, all of Delaware; Brahman Partners II Offshore Ltd., Brahman Partners IV (Cayman) Ltd., and East 71 Ltd., all of the Cayman Islands v. Teva Pharmaceutical Industries Ltd., of Israel; Erez Vigodman, Eyal Desheh, Sigurdur Olafsson, Deborah Griffin, Kåre Schultz, Michael McClellan, and Yitzhak Peterburg at the U. S. District Court for the District of Connecticut.
Topics
Cayman Islands Fraud Investment Israel Listed SecuritiesKeywords
BH Investments Funds LLC Brahman Partners II LP Brahman Partners II Offshore Ltd. Brahman Partners III LP Brahman Partners IV (Cayman) Ltd.